Faron Pharmaceuticals Oy (FRA:4FR) Total Equity: €-18.51 Mil (As of Dec. 2025)


FRA:4FR Faron Pharmaceuticals Oy FRA:4FR
21 GF Score
Price €0.51
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy Total Equity?

Faron Pharmaceuticals Oy FRA:4FR +7.68% 21 Total Equity is €-18.51 Mil as of Dec. 2025. GuruFocus rates FRA:4FR with a GF Score™ of 21/100. The stock has 4 warning signs investors should review.

Faron Pharmaceuticals Oy's total equity for the quarter that ended in Dec. 2025 was €-18.51 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Faron Pharmaceuticals Oy Total Equity Historical Data

* Premium members only.

The historical data trend for Faron Pharmaceuticals Oy's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Faron Pharmaceuticals Oy Total Equity Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.92 -11.48 -15.16 -9.76 -18.51

Faron Pharmaceuticals Oy Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.16 1.38 -9.76 -16.25 -18.51
FRA:4FR
21GF Score
Faron Pharmaceuticals Oy FRA:4FR
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Faron Pharmaceuticals Oy's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=17.172-35.679
=-18.51

Faron Pharmaceuticals Oy's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=17.172-35.679
=-18.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €-18.51 Mil mean?
Faron Pharmaceuticals Oy (FRA:4FR) has a Total Equity of €-18.51 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Faron Pharmaceuticals Oy and its competitors.
Is Faron Pharmaceuticals Oy's Total Equity too high?
Faron Pharmaceuticals Oy's current Total Equity is €-18.51 Mil. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's Total Equity compare to VRTX and REGN?
Faron Pharmaceuticals Oy's Total Equity of €-18.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Faron Pharmaceuticals Oy and its competitors. Faron Pharmaceuticals Oy's current Total Equity is €-18.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (FRA:4FR) has a current Total Equity of €-18.51 Mil. The current Total Equity is €-18.51 Mil. Faron Pharmaceuticals Oy's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (FRA:4FR), the current Total Equity is €-18.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARN:UKFARON:Finland
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
21GF Score

Get the complete analysis for FRA:4FR

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price